The Martinsried-based start-up Invitris, winner of the m4 Award coordinated by BioM, has been selected as one of 71 companies in the latest funding round of the EIC Accelerator. The biotech start-up impressed with its platform technology for the production of bacteriophages for the treatment of antibiotic-resistant infections and will receive a combination of grants and equity funding.
INVITRIS utilizes bacteriophages to treat antibiotic-resistant infections and has developed a unique technology that enables, for the first time, the in vitro production of genetically optimized bacteriophages for therapeutic use. The spin-off from the Technical University of Munich had already received funding through INCATE in 2022.
Winners of the EIC Accelerator receive up to EUR 2.5 million in grants, with some also benefiting from equity investments. Nearly 80% of the companies opt for blended finance, combining grants and equity investments.
In 2021, Invitris won the m4 Award, a pre-seed competition coordinated by BioM. Funded by the Free State of Bavaria, this award supports academic teams with high spin-off potential. The m4 Award provides a total of EUR 2.5 million for five teams and is awarded every two years.
The EIC Accelerator, a program of the European Commission, supports high-potential innovations with strong market prospects. More than 1,200 applications were submitted in the current funding round. With EIC Accelerator funding, Invitris aims to further advance its innovative platform technology for the development of next-generation phage therapeutics.